Related Experiment Video
Updated: Jun 24, 2026
12:45
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
Decrease of plasma N-terminal pro beta-type natriuretic peptide as a predictor of clinical improvement after cardiac
Li-Gang Ding1, Wei Hua, Shu Zhang
1Centre of Arrhythmia Diagnosis and Treatment, Cardiovascular Institute and Fu Wai Hospital, Chinese Academy and Medical Sciences & Peking Union Medical College, Beijing 100037, China.
Chinese Medical Journal
|March 28, 2009
Summary
The percentage change in N-terminal pro beta-type natriuretic peptide (NT pro BNP) levels after three months predicts long-term response to cardiac resynchronization therapy (CRT). NT pro BNP monitoring can simplify assessing CRT effectiveness.
Area of Science:
- Cardiology
- Biomarkers
- Heart Failure Management
Background:
- N-terminal pro beta-type natriuretic peptide (NT pro BNP) is a known prognostic indicator in heart failure.
- NT pro BNP can guide treatment decisions for heart failure patients.
- The predictive value of NT pro BNP for cardiac resynchronization therapy (CRT) response requires further investigation.
Purpose of the Study:
- To assess the utility of NT pro BNP in predicting clinical response to CRT.
- To determine if NT pro BNP levels can guide CRT treatment adjustments.
- To evaluate NT pro BNP as a monitoring tool for CRT outcomes.
Main Methods:
- 44 patients with chronic heart failure undergoing CRT implantation were studied.
- NT pro BNP levels were measured pre-implantation and at 3 months post-implantation.
- Clinical, echocardiographic, and exercise parameters were monitored, with ROC analysis used.
Main Results:
- Cardiac resynchronization therapy significantly reduced NT pro BNP levels in responders (P < 0.001).
- A significant reduction in NT pro BNP was observed in responders post-CRT.
- Percentage change in NT pro BNP (DeltaBNP%) at 3 months predicted long-term clinical improvement.
Conclusions:
- DeltaBNP% from baseline to 3 months post-CRT is a predictor of long-term CRT response.
- NT pro BNP serves as a simple method for monitoring the effects of CRT.
- Early changes in NT pro BNP can indicate the success of CRT.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...